MC Sciences

MC Sciences is an emerging biotechnology company developing a new class of therapies that target mast cells, the immune cells that drive allergic and inflammatory conditions, with the aim of treating a wide range of high-need diseases across allergy, respiratory, digestive, and inflammatory conditions. Its approach is built on the discovery of a key receptor that controls mast cell activity, opening the door to treatments designed to be both more effective and safer than existing options.


Website

mcsciences.com

Partner

Uwe Schoenbeck

Investment

Series A